Champions Oncology Q2 EPS $(0.15) Down From $0.01 YoY, Sales $11.60M Down From $14.28M YoY
Portfolio Pulse from Benzinga Newsdesk
Champions Oncology (NASDAQ:CSBR) experienced a significant decline in financial performance for Q2, with EPS dropping to $(0.15) from $0.01 YoY and sales falling to $11.60M from $14.28M YoY, representing a 1600% decrease in earnings and an 18.77% decrease in sales.
December 12, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Champions Oncology reported a substantial decrease in Q2 earnings and sales, with EPS falling to $(0.15) from $0.01 YoY and sales declining by 18.77% to $11.60M from $14.28M YoY.
The reported decrease in both earnings per share and sales is a strong negative signal for investors, indicating a significant downturn in the company's financial health. This is likely to result in a negative short-term impact on the stock price as investors react to the poor performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100